Diskusjon Triggere Porteføljer Aksjonærlister

BergenBio Fundamentale Forhold (BGBIO)

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre :slight_smile:

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

  1. @anon28800809 (279 likes)
  1. @Roc (146 likes)
  1. @vcp (102 likes)

Resten av topp 10:

  1. @Hayen (78 likes)

  2. @alfred_e_neuman (41 likes)

  3. @HeldigFyr (40 likes)

  4. @tverilytt (38 likes)

  5. @Direkte (37 likes)

  6. @Multiple (36 likes)

  7. @larosaleda (33 likes)

Gratulerer!

BERGENBIO TO PRESENT UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING

10 Likes

BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL DATA ON BEMCENTINIB IN STK11-POSITIVE NSCLC AT SITC ANNUAL MEETING 2021

6 Likes

BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB IN STK11-MUTATED ADVANCED/METASTATIC NON-SMALL LUNG CANCER (NSCLC)

23 Likes

Abstract SITC 2021

Conclusion / Summary
Lack of TCF1-expressing CD8 T cells prevents ICB efficacy in KPL tumors. Systemic inhibition of
AXL increased type I interferon secretion from dendritic cells that expanded tumor-associated
TCF1+ PD-1+ CD8 T cells and restored anti-PD-1 efficacy in STK11/LKB1 mutant tumors.
Anecdotally, NSCLC patients with identified STK11/LKB1 mutations receiving bemcentinib and
pembrolizumab demonstrated objective clinical response to combination therapy. These results
show that AXL is a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC

3 Likes

BerGenBio ASA: Increase of share capital, exercise of share options

Du jobber utrettelig💪 Håper Merck kjenner på sulten! En fase 3 partneravtale hadde smakt av fugl.

Fast track i både NSCLC og AML!
Må kunne sies å være en fantastisk validering av bemcentinib.

Så har vi alle de andre studiene i tillegg.

Verdsettelsen av selskapet derimot, synest å reflektere noe helt annet.

Ser fram til q3 presentasjon mandag!

6 Likes

https://newsweb.oslobors.no/message/546936

  • AML confirmayory trial H2 2022
  • NSCLC 1b i H1 2022. 1L ( STK11)
  • COVID multinational collaboration H1.
17 Likes

BerGenBio ASA: Share capital increase

https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20211116_4

3 Likes

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre :slight_smile:

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

  1. @anon28800809 (680 likes)
  1. @Roc (308 likes)
  1. @Hayen (120 likes)

Resten av topp 10:

  1. @vcp (107 likes)

  2. @Multiple (67 likes)

  3. @Scrivener (64 likes)

  4. @Ekornet (63 likes)

  5. @larosaleda (51 likes)

  6. @Fornybar (47 likes)

  7. @Matadoren (44 likes)

Gratulerer!

BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING

10 Likes

Virker jo lovende dette:

Gj.sn. alder på pasientene er 76 år, så man kan neppe forvente større økning i respons/overlevelse enn dette.

8 Likes

Ser på posteren at «survival data continues to mature».

1 Like

BerGenBio to present at DNB Nordic Healthcare Conference 2021

3 Likes

AXL receptor is required for Zika virus strain MR-766 infection in human glioblastoma cell lines

Published: November 10, 2021

https://www.cell.com/molecular-therapy-family/oncolytics/fulltext/S2372-7705(21)00150-9 (DOI)

Recent reports have shown that Zika virus (ZIKV) has oncolytic potential against human glioblastoma (GBM); however, the mechanisms underlying its tropism and cell entry are not completely understood. The receptor tyrosine kinase AXL has been identified as an entry receptor for ZIKV in a cell-type-specific manner. Interestingly, AXL is frequently overexpressed in GBM patients. Using commercially available GBM cell lines, we first show that cells expressing AXL are permissive for ZIKV infection, while cells that do not express AXL are not.

Furthermore, inhibition of AXL kinase using R428 and antibody blockade of AXL receptor strongly attenuated virus entry in GBM cell lines. Additionally, CRISPR knockout of the AXL gene in GBM cell lines completely abolished ZIKV infection, significantly inhibited viral replication, and significantly reduced apoptosis compared with parental lines. Lastly, introduction of AXL receptor into non-expressing cell lines renders the cells susceptible to ZIKV infection.

Together, these findings demonstrate that ZIKV entry into GBM cells in vitro is mediated by the AXL receptor and that following cell entry, productive infection is cytotoxic. Thus, ZIKV is a potential oncolytic virus for GBM.

(Bemcentinib, also known as BGB324 or R428)

18 Likes

Blir spennende å få resultatene fra Glioblastom studien i USA, tipper mot slutten av 2022.

2 Likes

BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center

15 Likes

BerGenBio ASA: Notice of Extraordinary General Meeting

2 Likes

Financial calendar